Literature DB >> 9039213

Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita.

H Kofler1, B Wambacher-Gasser, G Topar, G Weinlich, G Schuler, H Hintner, N Romani, P Fritsch.   

Abstract

Epidermolysis bullosa acquisita is an uncommon autoimmune bullous disease of the skin and mucous membranes. It is chronic, disabling, and difficult to treat. We describe a case of severe epidermolysis bullosa acquisita of 7 years' duration that had been treated with azathioprine, corticosteroids, chlorambucil, plasma exchanges, cyclophosphamide, cyclosporine, and colchicine without any lasting effect. Seven cycles of treatment were administered with immunoglobulin given intravenously at a low dose, 40 mg/kg body weight daily for 5 days. The patient was free of disease for 10 months after the initiation of therapy. We suggest that low-dose regimens of immunoglobulins may be as effective in this disease as the high-dose regimens suggested in the literature, and at much lower cost.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9039213     DOI: 10.1016/s0190-9622(97)80411-2

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

1.  High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders.

Authors:  S Jolles
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 2.  Epidermolysis bullosa acquisita.

Authors:  Rishu Gupta; David T Woodley; Mei Chen
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

Review 3.  Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen.

Authors:  Mei Chen; Gene H Kim; Lori Prakash; David T Woodley
Journal:  Autoimmunity       Date:  2011-09-28       Impact factor: 2.815

Review 4.  Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management.

Authors:  Minhee Kim; Luca Borradori; Dédée F Murrell
Journal:  Drugs Aging       Date:  2016-10       Impact factor: 3.923

5.  The Treatment of Lyell'S Syndrome: our Experience.

Authors:  B Napoli; N D'Arpa; M Masellis
Journal:  Ann Burns Fire Disasters       Date:  2006-03-31

Review 6.  Autoimmune bullous dermatoses in the elderly: diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 7.  High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.

Authors:  Norito Ishii; Takashi Hashimoto; Detlef Zillikens; Ralf J Ludwig
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

8.  Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2010-01-01       Impact factor: 3.923

9.  Therapy of autoimmune bullous diseases.

Authors:  Diya F Mutasim
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

Review 10.  Epidermolysis Bullosa Acquisita: The 2019 Update.

Authors:  Hiroshi Koga; Catherine Prost-Squarcioni; Hiroaki Iwata; Marcel F Jonkman; Ralf J Ludwig; Katja Bieber
Journal:  Front Med (Lausanne)       Date:  2019-01-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.